TPH1 and cancer: Given the strong antiangiogenic activity of BJ-1113 against VEGF [30], the inhibitory effects of BJ-1113 on the expressions of TPH1 and VEGF in MDA-MB-231 cells indicate BJ-1113 exhibits the properties required of an anti-cancer agent for tumors resistant to anti-VEGF therapy.